<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36810107</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study.</ArticleTitle><Pagination><StartPage>129</StartPage><MedlinePgn>129</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">129</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-023-07083-9</ELocationID><Abstract><AbstractText Label="BACKGROUNDS" NlmCategory="BACKGROUND">N-acetylcysteine (NAC) has broadly been used as an anti-oxidant agent in various types of diseases. This study aimed to assess the effect of NAC on the systemic lupus erythematosus (SLE) disease activity and outcome.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this randomized, double-blind clinical trial study, 80 SLE patients were recruited that were classified into two groups: 40 patients received NAC (1800 mg/day; 3 times per day with 8-h intervals) for 3 months and 40 patients as the control group received normal therapies. Laboratory measurements and disease activity based on the British Isles Lupus Assessment Group (BILAG) and SLE Disease Activity Index (SLEDAI) were determined before the initiation of treatment and after the study time period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A statistically significant decrease in BILAG (P= 0.023) and SLEDAI (P= 0.034) scores after receiving NAC for a 3-month period was observed. BILAG (P= 0.021) and SLEDAI (P= 0.030) scores were significantly lower in NAC-receiving patients compared to the control group after 3 months. The disease activity in each organ based on BILAG score after treatment indicated a significant decrease in the NAC group compared to the baseline level in general (P=0.018), mucocutaneous (P=0.003), neurological (P=0.015), musculoskeletal (P=0.048), cardiorespiratory (P=0.047), renal (P=0.025), and vascular (P=0.048) complications. Analysis indicated a significant increase in CH50 level in the NAC group after treatment compared to the baseline level (P=0.049). No adverse event was reported by the study subjects.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">It appears that the administration of 1800 mg/day NAC to SLE patients can decrease the SLE disease activity and its complications.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abbasifard</LastName><ForeName>Mitra</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Ali-Ibn Abi-Talib Hospital, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khorramdelazad</LastName><ForeName>Hossein</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rostamian</LastName><ForeName>Abdolrahman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rheumatology Research Center, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezaian</LastName><ForeName>Mohsen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biostatistics Group, Division of Epidemiology &amp; Health Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Askari</LastName><ForeName>Pooya Saeed</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharifi</LastName><ForeName>Gholamhosein Taghipur Khajeh</ForeName><Initials>GTK</Initials><AffiliationInfo><Affiliation>Department of Surgery, Ali-Ibn-Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parizi</LastName><ForeName>Moein Kardoust</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharifi</LastName><ForeName>Mobina Taghipour Khajeh</ForeName><Initials>MTK</Initials><AffiliationInfo><Affiliation>School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Najafizadeh</LastName><ForeName>Seyed Reza</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Rheumatology Research Center, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran. najafisr@tums.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>WYQ7N0BPYC</RegistryNumber><NameOfSubstance UI="D000111">Acetylcysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000111" MajorTopicYN="Y">Acetylcysteine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-oxidant</Keyword><Keyword MajorTopicYN="N">BILAG</Keyword><Keyword MajorTopicYN="N">N-acetylcysteine</Keyword><Keyword MajorTopicYN="N">SLEDAI</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>14</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36810107</ArticleId><ArticleId IdType="pmc">PMC9945717</ArticleId><ArticleId IdType="doi">10.1186/s13063-023-07083-9</ArticleId><ArticleId IdType="pii">10.1186/s13063-023-07083-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buyon JP. Systemic Lupus Erythematosus. In: Klippel JH, Stone JH, Crofford LJ, White PH, editors. Primer on the Rheumatic Diseases. New York: Springer; 2008. 10.1007/978-0-387-68566-3_15.</Citation></Reference><Reference><Citation>Gualtierotti R, Biggioggero M, Penatti A, Meroni P. Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2010;10(1):3&#x2013;7. doi: 10.1016/j.autrev.2010.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2010.09.007</ArticleId><ArticleId IdType="pubmed">20863908</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasifard M, Kamiab Z, Hasani M, Rahnama A, Saeed-Askari P, Khorramdelazad H. Assessing the expression of immunosuppressive cytokines in the newly diagnosed systemic lupus Erythematosus patients: a focus on B cells. BMC Immunol. 2020;21(1):1&#x2013;12. doi: 10.1186/s12865-020-00388-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-020-00388-3</ArticleId><ArticleId IdType="pmc">PMC7670657</ArticleId><ArticleId IdType="pubmed">33198645</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis &amp; Rheumatism: Official Journal of the American College of. Rheumatology. 1991;34(8):937&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">1859487</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder JO, Euler HH. Recognition and management of systemic lupus erythematosus. Drugs. 1997;54(3):422&#x2013;434. doi: 10.2165/00003495-199754030-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-199754030-00005</ArticleId><ArticleId IdType="pubmed">9279504</ArticleId></ArticleIdList></Reference><Reference><Citation>Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001;13(5):345&#x2013;351. doi: 10.1097/00002281-200109000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002281-200109000-00002</ArticleId><ArticleId IdType="pubmed">11604587</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginzler EM, Moldovan I. Systemic lupus erythematosus trials: successes and issues. Curr Opin Rheumatol. 2004;16(5):499&#x2013;504. doi: 10.1097/01.bor.0000133659.14482.59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.bor.0000133659.14482.59</ArticleId><ArticleId IdType="pubmed">15314485</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H-T, Wu T-H, Lin C-S, Lee C-S, Wei Y-H, Tsai C-Y, et al. The pathogenesis of systemic lupus erythematosus-From the viewpoint of oxidative stress and mitochondrial dysfunction. Mitochondrion. 2016;30:1&#x2013;7. doi: 10.1016/j.mito.2016.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2016.05.007</ArticleId><ArticleId IdType="pubmed">27235747</ArticleId></ArticleIdList></Reference><Reference><Citation>Gergely P, Jr, Grossman C, Niland B, Puskas F, Neupane H, Allam F, et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 2002;46(1):175&#x2013;190. doi: 10.1002/1529-0131(200201)46:1&lt;175::AID-ART10015&gt;3.0.CO;2-H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(200201)46:1&lt;175::AID-ART10015&gt;3.0.CO;2-H</ArticleId><ArticleId IdType="pmc">PMC4020417</ArticleId><ArticleId IdType="pubmed">11817589</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai ZW, Hanczko R, Bonilla E, Caza TN, Clair B, Bartos A, et al. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012;64(9):2937&#x2013;2946. doi: 10.1002/art.34502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34502</ArticleId><ArticleId IdType="pmc">PMC3411859</ArticleId><ArticleId IdType="pubmed">22549432</ArticleId></ArticleIdList></Reference><Reference><Citation>Suwannaroj S, Lagoo A, Keisler D, McMurray RW. Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus. 2001;10(4):258-65. 10.1191/096120301680416940.</Citation><ArticleIdList><ArticleId IdType="pubmed">11341102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewthanom K, Janwityanujit S, Totemchockchyakarn K, Panomvana D. Pharmacodynamic effect of N-acetylcysteine as adjunctive therapy in mild systemic lupus erythematosus patients. Trop J Pharm Res. 2011;10(2). 10.4314/tjpr.v10i2.66554.</Citation></Reference><Reference><Citation>Doherty E, Oaks Z, Perl A. Increased mitochondrial electron transport chain activity at complex I is regulated by N-acetylcysteine in lymphocytes of patients with systemic lupus erythematosus. Antioxid Redox Signal. 2014;21(1):56&#x2013;65. doi: 10.1089/ars.2013.5702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2013.5702</ArticleId><ArticleId IdType="pmc">PMC4048573</ArticleId><ArticleId IdType="pubmed">24673154</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewthanom K, Janwitayanujit S, Totemchockcyakarn K, Ayudhya PN, D. The effect of high dose of N-acetylcysteine in lupus nephritis: a case report and literature review. J Clin Pharm Ther. 2010;35(4):483&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">20831550</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia RJ, Francis L, Dawood M, Lai ZW, Faraone SV, Perl A. Brief report: attention deficit and hyperactivity disorder scores are elevated and respond to n-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(5):1313&#x2013;1318. doi: 10.1002/art.37893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37893</ArticleId><ArticleId IdType="pmc">PMC4034122</ArticleId><ArticleId IdType="pubmed">23400548</ArticleId></ArticleIdList></Reference><Reference><Citation>Perl A, Hanczko R, Telarico T, Oaks Z, Landas S. Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase. Trends Mol Med. 2011;17(7):395&#x2013;403. doi: 10.1016/j.molmed.2011.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2011.01.014</ArticleId><ArticleId IdType="pmc">PMC3116035</ArticleId><ArticleId IdType="pubmed">21376665</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee R, Margaritis M, Channon M, K, Antoniades C. Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations. Curr Med Chem. 2012;19(16):2504&#x2013;2520. doi: 10.2174/092986712800493057.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986712800493057</ArticleId><ArticleId IdType="pmc">PMC3412204</ArticleId><ArticleId IdType="pubmed">22489713</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepel M, Van Der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation. 2003;107(7):992&#x2013;995. doi: 10.1161/01.CIR.0000050628.11305.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000050628.11305.30</ArticleId><ArticleId IdType="pubmed">12600912</ArticleId></ArticleIdList></Reference><Reference><Citation>Machlin LJ, Bendich A. Free radical tissue damage: protective role of antioxidant nutrients. FASEB J. 1987;1(6):441&#x2013;445. doi: 10.1096/fasebj.1.6.3315807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.1.6.3315807</ArticleId><ArticleId IdType="pubmed">3315807</ArticleId></ArticleIdList></Reference><Reference><Citation>Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353(21):2229&#x2013;2242. doi: 10.1056/NEJMoa042976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa042976</ArticleId><ArticleId IdType="pubmed">16306520</ArticleId></ArticleIdList></Reference><Reference><Citation>Perl A, Hanczko R, Lai Z-W, Oaks Z, Kelly R, Borsuk R, et al. Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin. Metabolomics. 2015;11(5):1157&#x2013;1174. doi: 10.1007/s11306-015-0772-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11306-015-0772-0</ArticleId><ArticleId IdType="pmc">PMC4559110</ArticleId><ArticleId IdType="pubmed">26366134</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinscherf R, Cafaltzis K, R&#xf6;der F, Hildebrandt W, Edler L, Deigner H-P, et al. Cholesterol levels linked to abnormal plasma thiol concentrations and thiol/disulfide redox status in hyperlipidemic subjects. Free Radic Biol Med. 2003;35(10):1286&#x2013;1292. doi: 10.1016/j.freeradbiomed.2003.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2003.07.001</ArticleId><ArticleId IdType="pubmed">14607527</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>